Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Shuttle Pharmaceuticals Inc(SHPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SHPH
09/25/2026: SHPH (1-star) is currently NOT-A-BUY. Pass it for now.
Shuttle Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel radiation sensitizers to improve cancer treatment outcomes. Its primary strength lies in its specialized academic foundation and targeted R&D approach toward radiation oncology. The company's main investment story rests on the potential success of its clinical-stage pipeline, which offers high growth prospects. However, it faces significant risks including the lack of commercial revenue, high clinical failure potential, and competition from better-resourced oncology firms. This stock is best suited for growth-oriented investors with a high risk tolerance who are willing to monitor clinical development updates, regulatory filings, and the company's ability to maintain sufficient cash reserves.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success, but carries extreme binary risk. |
| Momentum investor | Mixed fit | Momentum may occur around clinical data releases, but is highly speculative and short-term. |
| Value investor | Weak fit | The company has no revenue or earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and is unlikely to do so in the near future. |
| Low-risk investor | Weak fit | The high volatility and clinical risk profile are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial outcomes and financing news. |
| Valuation risk | High | Without revenue, valuation is based on speculative future success, which can lead to significant repricing. |
| Competition risk (Oncology drug development) | Medium / high | The company faces competition from well-funded firms developing alternative cancer therapies. |
| Business quality | Medium | The company is early-stage, meaning its commercial franchise quality is yet to be established. |
| Dividend income | Low / none | There is no expectation of dividend income for the foreseeable future. |
| Execution risk | High | Success depends entirely on the technical and clinical execution of its therapeutic pipeline. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -43.9% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.35M USD | Price to earnings Ratio 40.1 | 1Y Target Price - |
Price to earnings Ratio 40.1 | 1Y Target Price - | ||
Volume (30-day avg) 48.8K shares | Beta 1.22 | 52 Weeks Range 2.58 - 55.90 | Updated Date 09/25/2026 |
52 Weeks Range 2.58 - 55.90 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and development of radiation sensitizers. | The company does not currently sell products and burns cash to develop drugs. |
Valuation
Trailing PE 40.1 | Forward PE - | Enterprise Value 1.22M | Price to Sales(TTM) - |
Enterprise Value 1.22M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.67 | Shares Outstanding 585.13K | Shares Floating 4.74M |
Shares Outstanding 585.13K | Shares Floating 4.74M | ||
Percent Insiders 0.84 | Percent Institutions 1.93 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Shuttle Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Gaithersburg, MD, United States | ||
IPO Launch date 2022-08-31 | Interim Co-CEO & Director Mr. Christopher Robert Cooper BBA, M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.shuttlepharma.com |
Full time employees 2 | Website https://www.shuttlepharma.com | ||
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.